🔎 Trials Near Me

Acasă › Leucemie mieloasă acută › New York

Studii clinice pentru Leucemie mieloasă acută în New York

71 studii pentru Leucemie mieloasă acută caută participanți în New York.

Orașe în New York

Text oficial al studiului (în engleză)

A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)

  • Montefiore Medical Center - Moses Campus /ID# 279399, The Bronx
În curs de recrutareFaza 2/3
Vârste de 18 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07581002

Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
În curs de recrutareFaza 2
Vârste de 60 ani și peste · Toate sexele · Actualizat 2 oct. 2026 · NCT07437950

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Queens Hospital Center, Jamaica
  • NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York
  • Stony Brook University Medical Center, Stony Brook
În curs de recrutareStudiu observaționalVoluntari sănătoși bineveniți
Vârste de la 40 la 75 · Toate sexele · Actualizat 2 oct. 2026 · NCT05334069

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center, New York
  • și încă 1
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 1 oct. 2026 · NCT06484062

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

  • Memorial Sloan Kettering Cancer Center, New York
În curs de recrutareFaza 1
Vârste de la 12 la 78 · Toate sexele · Actualizat 29 sept. 2026 · NCT03802695

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Mount Sinai Hospital, New York
  • și încă 5
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 28 sept. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Memorial Sloan Kettering Cancer Center, New York
  • New York Presbyterian - Weill Cornell, New York
  • și încă 2
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT06852222

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Northwell Health/Center for Advanced Medicine, Lake Success
  • și încă 9
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 sept. 2026 · NCT05564390

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

  • Roswell Park Cancer Institute, Buffalo
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 24 sept. 2026 · NCT06871410

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

  • Memorial Sloan Kettering Cancer Center, New York
În curs de recrutareFaza 1
Până la vârsta de 21 · Toate sexele · Actualizat 23 sept. 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Northwell Health/Center for Advanced Medicine, Lake Success
  • și încă 5
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06317649

A Study of CRD3874-SI in People With Leukemia

  • Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (All protocol activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • și încă 1
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT07661095

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • și încă 4
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 sept. 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

  • Roswell Park Cancer Institute, Buffalo
  • Memorial Sloan Kettering Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • și încă 9
În curs de recrutareFaza 2
Vârste de la 18 la 59 · Toate sexele · Actualizat 22 sept. 2026 · NCT05554406

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

  • Memorial Sloan Kettering Cancer Center, New York
În curs de recrutareFaza 1/2
Vârste de 12 ani și peste · Toate sexele · Actualizat 18 sept. 2026 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • Roswell Park Cancer Institute, Buffalo
  • și încă 11
În curs de recrutareFaza 3
6 Months – 21 Years · Toate sexele · Actualizat 17 sept. 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • Montefiore Medical Center, New York
În curs de recrutareFaza 1/2
30 Days · Toate sexele · Actualizat 16 sept. 2026 · NCT04065399

Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission

  • Weill Cornell, New York
  • Clinical Research Allicance, Westbury
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 16 sept. 2026 · NCT06824168

A Telehealth Advance Care Planning Intervention

  • University of Rochester, Rochester
În curs de recrutare
Vârste de 60 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT05875805

Cord Blood Transplant in Adults With Blood Cancers

  • Memorial Sloan Kettering Cancer Center, New York
În curs de recrutareFaza 2
Vârste de la 21 la 65 · Toate sexele · Actualizat 11 sept. 2026 · NCT05884333

A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)

  • Roswell Park Comprehensive Cancer Center, Buffalo
În curs de recrutareFaza 1/2
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 sept. 2026 · NCT06969430

A Study to Assess Adverse Events and How Intravenous (IV) Pivekimab Sunirine Moves Through the Body in Pediatric Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

  • New York Medical College /ID# 275597, Valhalla
În curs de recrutareFaza 1
6 Months – 17 Years · Toate sexele · Actualizat 9 sept. 2026 · NCT07306832

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Albany Medical Center, Albany
  • Montefiore Medical Center - Moses Campus, The Bronx
În curs de recrutareFaza 3
Vârste de la 1 la 25 · Toate sexele · Actualizat 4 sept. 2026 · NCT07022678

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • Memorial Sloan Kettering Cancer Center, New York
  • Memorial Sloan Kettering Cancer Center, New York
  • Montefiore Medical Center, New York
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 25 aug. 2026 · NCT06533761

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Albany Medical Center, Albany
  • Maimonides Medical Center, Brooklyn
  • NYU Langone Hospital - Long Island, Mineola
  • și încă 7
În curs de recrutareFaza 1/2
Până la vârsta de 22 · Toate sexele · Actualizat 25 aug. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Columbia University Irving Medical Center, New York
  • Memorial Sloan Kettering Cancer Center - New York, New York
  • Cohen Children's Medical Center, Queens
În curs de recrutareFaza 3
29 Days – 21 Years · Toate sexele · Actualizat 24 aug. 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • State University of New York at Buffalo, Buffalo
  • Icahn School of Medicine at Mount Sinai, New York
  • Columbia University, New York
  • și încă 1
În curs de recrutareFaza 3
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT07007312

Acute Myeloid Leukemia and Markers of Leukemia Stem Cells (CLL1 and CD45RA)

  • Stony Brook Cancer Center, Stony Brook
În curs de recrutareStudiu observațional
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT06297551

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Roswell Park Comprehensive Cancer Center, Buffalo
  • Northwell Health, LLC PRIME, Lake Success
  • Memorial Sloan Kettering Cancer Center, New York
  • și încă 3
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 20 aug. 2026 · NCT06001788

ICP-248 in Combination With Azacitidine for the Treatment in Patients With Myeloid Malignancies

  • NYU Langone Health, New York
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 18 aug. 2026 · NCT06656494

Olutasidenib DDI Study in Patients With IDH1 Mutation Positive Malignancies

  • New York Presbyterian Hospital-Columbia University Medical Center, New York
În curs de recrutareFaza 4
Vârste de 18 ani și peste · Toate sexele · Actualizat 11 aug. 2026 · NCT07486713

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Memorial Sloan- Kettering Cancer Center, New York
În curs de recrutareFaza 1
Vârste de la 1 la 30 · Toate sexele · Actualizat 3 aug. 2026 · NCT06177067

Study of AZD3632 Monotherapy or in Combination With Anticancer Agents in Participants With Advanced Haematologic Malignancies With KMT2Ar, NPM1m, or Other Genotypes Associated With HOX Overexpression

  • Research Site, New York
În curs de recrutareFaza 1/2
Vârste de 16 ani și peste · Toate sexele · Actualizat 20 iul. 2026 · NCT07155226

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

  • University of Rochester Medical Center (URMC), Rochester
În curs de recrutareFaza 3
Vârste de la 18 la 75 · Toate sexele · Actualizat 17 iul. 2026 · NCT05429632

A Study of the Combination of Ivosidenib, Azacitidine, and Venetoclax Followed by Ivosidenib Alone in People With Acute Myeloid Leukemia

  • Memorial Sloan Kettering Suffolk- Commack (Limited Protocol Activities), Commack
  • Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • și încă 1
În curs de recrutareFaza 2
Vârste de 60 ani și peste · Toate sexele · Actualizat 17 iul. 2026 · NCT07392242

Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents

  • Roswell Park Cancer Institute, Buffalo
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 10 iul. 2026 · NCT05442216

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

  • Weill Cornell Medicine - New York Presbyterian Hospital, New York
În curs de recrutareFaza 2
Vârste de 18 ani și peste · Toate sexele · Actualizat 7 iul. 2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Roswell Park Cancer Institute, Buffalo
  • North Shore University Hospital, Lake Sucess
  • Cohen Children's Medical Center of New York, New Hyde
  • și încă 9
În curs de recrutareStudiu observațional
Toate vârstele · Toate sexele · Actualizat 6 iul. 2026 · NCT01351545

A Decisional Intervention for Older Adults With Acute Myeloid Leukemia and Their Caregivers

  • University of Rochester Medical Center, Rochester
În curs de recrutare
Vârste de 60 ani și peste · Toate sexele · Actualizat 6 iul. 2026 · NCT06697600

A Study of Gilteritinib in Combination With Ivosidenib or Enasidenib in People With Acute Myeloid Leukemia (AML)

  • Memorial Sloan Kettering Suffolk-Commack, Commack
  • Memorial Sloan Kettering Westchester, Harrison
  • Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York
  • și încă 1
În curs de recrutareFaza 1
Vârste de 18 ani și peste · Toate sexele · Actualizat 22 iun. 2026 · NCT05756777

Sursă: ClinicalTrials.gov, date preluate la 5 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.